University of New England licenses cancer biomarker test to Satya Diagnostics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The University of New England recently signed its first intellectual property license agreement with Satya Diagnostics—a company that recently received $100,000 in MaineHealth Bonfire Funding to help it achieve its goal of improving cancer detection and treatment in communities across the world.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The definition of “therapeutic imperative” is this: A treatment necessity that must be met in order to prevent death. Once the imperative is clearly defined, addressing it properly links correct diagnosis with therapy and favorable prognosis. On the other hand, misdiagnosis or inadequate diagnosis fails to provide a framework for highly effective or curative therapy. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login